Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis-Reference-Cited by-同舟云学术

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Published:2017-08-31 Issue:9 Volume:130 Page:1132-1143
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Machlus Kellie R.¹^ORCID,Wu Stephen K.¹,Vijey Prakrith¹,Soussou Thomas S.¹,Liu Zhi-Jian²³,Shacham Eran⁴,Unger T. J.⁴,Kashyap Trinayan⁴,Klebanov Boris⁴,Sola-Visner Martha²³,Crochiere Marsha⁴,Italiano Joseph E.¹⁵,Landesman Yosef⁴

Affiliation:

1. Division of Hematology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA;

2. Department of Pediatrics, Harvard Medical School, Boston, MA;

3. Division of New Born Medicine, Boston Children's Hospital, Boston, MA;

4. Karyopharm Therapeutics, Newton, MA; and

5. Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Boston, MA

Abstract

Key Points XPO1 blockade causes thrombocytopenia by inhibiting TPO signaling and blocking the differentiation of stem cells into megakaryocytes. Selinexor-induced thrombocytopenia is reversible when TPO agonists are administered in the absence of selinexor (drug holiday).

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/9/1132/1405199/blood752840.pdf

Reference34 articles.

1. Choreography of importin-α/CAS complex assembly and disassembly at nuclear pores;Sun;Proc Natl Acad Sci USA,2013

2. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy;Tan;Cancer Discov,2014

3. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing;Neggers;Chem Biol,2015

4. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia;Lapalombella;Blood,2012

5. Identification of nuclear export inhibitors with potent anticancer activity in vivo;Mutka;Cancer Res,2009

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07

2. A novel application of XPO1 inhibition for the treatment of myelofibrosis;Blood Neoplasia;2024-06

3. Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database;Scientific Reports;2024-05-28

4. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials;Clinical and Translational Medicine;2024-05

5. MiRNA-296-5p promotes the sensitivity of nasopharyngeal carcinoma cells to cisplatin via targeted inhibition of STAT3/KLF4 signaling axis;Scientific Reports;2024-03-20